Number of deaths attributable to benfluorex;Mortalité attribuable au benfluorex (Mediator ®)

Presse Medicale

Volumn 40, Issue 5, 2011, Pages 462-469

  Hill Catherine, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; MEDIATOR (DRUG); UNCLASSIFIED DRUG;

CAUSAL ATTRIBUTION; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; FRANCE; HUMAN; MORTALITY; SHORT SURVEY;

CAUSE OF DEATH; DRUG TOXICITY; FENFLURAMINE; HUMANS; HYPOLIPIDEMIC AGENTS;

EID: 79955467882     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.03.001     Document Type: Short Survey

References (15)

1. Jacques Servier. Le Monde, 21 novembre 2010.
2. Marié A. Médiator. Les faits et les spéculations. Quotidien du Médecin 2010, 6(8870):5.
3. Derumeaux G. Affaire Mediator « il faut rester factuel ». Propos recueilli par Anne Teyssédou. Consensus Cardio 2010, 84:24-25.
4. - Publié le 16/11/2010 à 18:42 - Modifié le 17/11/2010 à 09:54. http://www.lepoint.fr/chroniqueurs-du-point/anne-jeanblanc/mediator-le-pr-bruckert-decrypte-les-dessous-de-l-affaire-16-11-2010-1263093_57.php.%20Le%20Point.fr.
5. Acar J. Benfluorex, valvulopathies et décès un autre regard. http://www.cardiologie-francophone.com/PDF/benfluorex-pr-acar.pdf.
6. Frachon I., Etienne Y., Jobic Y., Le Gal G., Humbert M., Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One 2010, 5(4):e10128.
7. Tribouilloy C., Rusinaru D., Henon P., Tribouilloy L., Leleu F., Andréjak M., Sevestre H., Peltier M., Caus T. Restrictive organic mitral regurgitation associated with benfluorex therapy. Eur J Echocardiogr 2010, 11(7):614-621.
8. Habib G. Communication à la 21ème Journée de la Société Française de Cardiologie 2011. http://www.cardio-sfc.org/activites/informations/communiques-de-la-sfc/en-direct-des-journees-europeennes-vendredi-14-janvier/conference/evolution-et-suivi-des-valvulopathies-associees-au-benfluorex-gilbert-habib/%3Fsearchterm=habib%20diapositive%2017/22.
9. http://www.afssaps.fr/var/afssaps_site/storage/original/application/d3586501cd537d588059288f37135194.pdf.
10. Weill A., Païta M., Tuppin P., Fagot J.P., Neumann A., Simon D., et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010, 19(12):1256-1262.
11. Bradford-Hill, Austin The Environment and Disease: association or Causation?. J R Soc Med 1965, 58:295-300.
12. http://www.afssaps.fr/content/download/29424/387817/version/1/file/point-info-Mediator-Etude_Cnam.pdf.
13. http://www.afssaps.fr/content/download/29426/387831/version/2/file/point-info-Mediator-Etude_complementaire_Cnam.pdf.
14. Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Maréchaux S, Eicher JC, et al. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Eur J Echocardiogr 2010, [Epub ahead of print]. doi:10.1093/ejechocard/jeq172.
15. Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K., et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010, 96:199-203.